ChromaDex® to Distribute IsoLife Stable Isotope Labeled Phytochemicals and Plant Products

IRVINE, Calif. and WAGENINGEN, Netherlands, Jan. 22, 2013 /PRNewswire/ -- ChromaDex^® Corporation (OTCQB: CDXC) ("ChromaDex") an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries, announced today it has signed a distribution agreement with IsoLife bv, which provides stable isotope labeled phytochemicals and plant products. These ¹³C- and ¹⁵N-labeled phytochemicals and plant products are used as tracers and internal standards for food & beverage, nutraceutical, pharmaceutical, cosmeceutical and environmental sciences research.

"The IsoLife agreement will add to ChromaDex's comprehensive and growing catalog, which contains more than 3,000 phytochemicals and 500 botanical reference materials," said Frank Jaksch, CEO and co-founder of ChromaDex. "By adding the IsoLife stable isotope materials to our portfolio, we continue our commitment to providing access to key materials to the research community, helping to facilitate important research for the Life Science industry."

Ton Gorissen and Ries de Visser, directors and founders of IsoLife, note the co-operation with ChromaDex is a natural extension of IsoLife's activities. "By using the excellent sales force of ChromaDex, we will be much better able to serve Life Science research needs in the overseas markets. The non-labeled and stable isotope-labeled products of both companies perfectly match and complement each other."

About ChromaDex^®:

ChromaDex, Inc. is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries. ChromaDex's pipeline of proprietary products includes patented pTeroPure^® pterostilbene, which was named the 2010 North American Most Promising Ingredient of the Year by the independent research company Frost & Sullivan. The company has also launched ProC3G™, a natural black rice extract containing 40% cyanidin-3-glucoside; NutraGAC™, a Gac fruit powder rich in lycopene and beta-carotene; and pteroberry™, an organic blend of pterostilbene, cranberry and blueberry. ChromaDex is also in the process of developing Nicotinamide Riboside, a novel next-generation B-vitamin. All products are backed with extensive scientific research and intellectual property.

About IsoLife:

IsoLife bv was established in 2005 as a spin-off company of Wageningen University & Research Center, The Netherlands. IsoLife develops, produces and sells uniformly stable isotope labeled (> 97 atom %) plant parts and their phytochemicals. Their stable isotope labeling facilities consist of fully computer controlled closed-system labeling chambers which are unique worldwide. IsoLife's products are used as tracers and internal standards in research and diagnostics in the Life Sciences by private companies and public research organizations worldwide. They are non-radioactive and allow non-invasive techniques that are completely safe and consumer, patient and environment-friendly. IsoLife has been identified by FEM Business Tech 25 as one of 25 young, innovative companies who 'shake the market with brilliant ideas.'

Forward-Looking Statements:

Any statements that are not historical facts contained in this release are "forward-looking statements" as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in the companies' filings with the Securities and Exchange Commission, and risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the companies do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

ChromaDex Investor Contact:
The Del Mar Consulting Group, Inc.
Robert B. Prag, President
858-794-9500
[email protected]

or

Alex Partners, LLC
Scott Wilfong, President
425-242-0891
[email protected]

ChromaDex Contact:
Laura Carney, Executive Assistant
949-419-0288
[email protected]

SOURCE ChromaDex, Inc.